Evidence supporting the use of: Cannabigerol
For the health condition: Convulsions

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Cannabigerol (CBG) is a non-psychoactive cannabinoid found in Cannabis sativa. Its use in supporting or treating convulsions and seizure disorders has some basis in emerging scientific research, although the evidence is still preliminary and largely derived from preclinical studies. Animal studies, such as those involving mice and rats, have demonstrated that CBG possesses anticonvulsant properties. For example, a 2021 study published in "Epilepsia" reported that CBG reduced seizure severity in mouse models of epilepsy. The mechanism is thought to involve modulation of several molecular targets, including cannabinoid receptors (CB1 and CB2), as well as potential effects on GABAergic and glutamatergic neurotransmission, both of which play central roles in neuronal excitability and seizure activity.

However, clinical data in humans are currently lacking. Most clinical research on cannabinoids and seizures has focused on cannabidiol (CBD), which has shown significant efficacy in specific forms of pediatric epilepsy, leading to the approval of Epidiolex. In contrast, there are no large-scale clinical trials or regulatory approvals for CBG in the treatment of convulsions. Therefore, while there is some early scientific rationale and animal-based evidence, the overall strength of evidence remains low, and much more research is needed before CBG can be considered a validated treatment for convulsions in humans.

More about Cannabigerol
More about Convulsions

Products containing Cannabigerol

We currently have no products on Vitabase that contain this ingredient.